Skip to content
Clinical Trials – home

Region Oestergoetland

Verified siteinfo

Sweden Universitetssjukhuset I Linkoping, 581 85 Linkoping, Sweden

  • 8 trials recruiting
  • Endometrial cancer · Atrial fibrillation · Acute lymphocytic leukaemia
  • Adults and children

About Specializations

Region Oestergoetland in Linkoping, Sweden specialises in clinical trials of conditions such as Endometrial cancer, Atrial fibrillation, Acute lymphocytic leukaemia, Adenocarcinoma of colon, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, focusing on innovative treatments for various cancers. The center's work in this field is driven by a commitment to improving patient outcomes through cutting-edge therapies and personalized medicine.

  • Generalized Mantle Cell Lymphoma
  • Ovarian Cancer
  • Uveal Melanoma Liver Metastases
  • Acute Myeloid Leukemia
  • Cutaneous Malignant Melanoma

By integrating clinical trials with translational research, the center is advancing the understanding of cancer biology and developing novel therapeutic strategies.

Gastroenterology

Specializing in gastroenterology, the center conducts pioneering research to address complex digestive disorders. The focus is on enhancing diagnostic techniques and therapeutic interventions to improve patient care.

  • Crohn's Disease
  • Ulcerative Colitis
  • Resected Pancreatic Ductal Adenocarcinoma

Through collaborative efforts, the center is developing innovative treatments that aim to improve quality of life for patients with chronic gastrointestinal conditions.

Cardiology

The center excels in cardiology research, focusing on the prevention and treatment of cardiovascular diseases. By leveraging advanced technologies and clinical expertise, the center is making significant strides in this critical field.

  • Coronary Artery Disease
  • Atrial Fibrillation
  • Heart Failure with Preserved Ejection Fraction

Research efforts are directed towards understanding the underlying mechanisms of heart diseases and developing effective therapeutic interventions.

Endocrinology

In the realm of endocrinology, the center is dedicated to advancing the treatment of metabolic and hormonal disorders. The research is aimed at improving patient outcomes through innovative therapies and personalized care.

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Thyroid Eye Disease

The center's research initiatives are focused on understanding the pathophysiology of endocrine disorders and developing novel treatment modalities.

Nephrology

Leading in nephrology research, the center is committed to improving the diagnosis and treatment of kidney diseases. The research is focused on innovative approaches to enhance renal function and patient care.

  • C3 Glomerulopathy
  • IgA Nephropathy

Through cutting-edge research, the center aims to develop new therapies that can significantly improve the quality of life for patients with chronic kidney conditions.

Neurology

The center's neurology research is dedicated to understanding and treating neurological disorders. The focus is on developing innovative therapies to improve patient outcomes and quality of life.

  • Major Depressive Disorder
  • Facial Nerve Palsy

By integrating clinical research with advanced neuroscience, the center is at the forefront of developing new treatments for complex neurological conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Universitetssjukhuset I Linkoping581 85 LinkopingSweden
Recruiting now
8 trials
Conditions studied
23
Partner status
Verified site

More sites in LinkopingSweden

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

22 clinical trials

Study of personalized tamoxifen dosing (10mg, 20mg, or 40mg daily) compared to standard dose (20mg) in women with breast cancer to improve treatment continuation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tamoxifen
  • Sponsor:Karolinska Institutet

Study Comparing Ipilimumab and Nivolumab to Nivolumab Alone for Patients with Resectable Stage III Melanoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Karolinska University Hospital

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Study Comparing Chemoradiotherapy with Fluorouracil, Cisplatin, and Carboplatin for Patients with Operable Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Karolinska University Hospital

Study on Apixaban for Preventing Stroke in Patients with Atrial Fibrillation and Stage 5 Chronic Kidney Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Karolinska University Hospital

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lixudebart
  • Sponsor:Alentis Therapeutics AG

Study Comparing R-MINI-CHOP and R-MINI-CHP with Polatuzumab Vedotin for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older or Frail Patients Aged 75 and Older

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Region Skane

Follicular lymphoma

Not recruiting

Phase II Study of ME-401, Rituximab and Bendamustine as First‑Line Treatment for High‑Risk and Low‑Risk Follicular Lymphoma Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Karolinska University Hospital

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.